HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on UroGen Pharma (NASDAQ: URGN) and maintained a price target of $75 for the stock. No additional financial figures or strategic changes were mentioned in the article.